Received radiotherapy to metastatic sites of disease < weeks prior to Day . Must be weeks from radiotherapy; if patients are within weeks of radiotherapy, then the progressive lesion must be outside of the high-dose radiation target volume or have unequivocal evidence of progressive tumor on a biopsy specimen ELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP ): Radiotherapy may be given before or after protocol treatment. when radiotherapy is planned prior to protocol treatment administration, patients must have completed adjuvant radiotherapy >= weeks prior to randomization for protocol therapy, if applicable Patients receiving adjuvant radiotherapy within weeks prior to randomization Radiotherapy within weeks of first dose of study drug Chemotherapy or stereotactic radiotherapy within the last weeks Less than four weeks since last radiotherapy (excluding palliative radiotherapy). Washout time of at least weeks for prior biological, chemotherapeutic, or radiotherapy Prior radiotherapy within weeks of the first dose of study treatment Radiotherapy: weeks PHASE II INCLUSION CRITERIA: For patients who do not receive radiotherapy after chemotherapy, the randomization must occur within weeks of the last chemotherapy cycle; the study treatment must start within weeks from randomization; for patients who receive radiotherapy (including prophylactic cranial radiation and/or thoracic radiation) after chemotherapy, the randomization must occur within weeks of the last chemotherapy cycle but at least weeks after completion of radiotherapy and the first dose of Lu-DOTA-Tyr-octreotate cannot be given within weeks of radiotherapy Has received prior radiotherapy within weeks of therapy. Participants who have had radiotherapy within weeks Patients who have had radiotherapy within weeks Radiotherapy within weeks of the first dose of study drug, with the exception of palliative radiotherapy to a limited field radiotherapy within weeks prior to treatment with APSF (intensive radiotherapy within weeks or palliative radiotherapy within weeks). Treatment must begin at a minimum of weeks after, but no later than weeks after, the date of completion of radiotherapy. Patient who has received radiotherapy =< weeks prior to study entry. Palliative radiotherapy for symptomatic control is acceptable (if completed at least weeks prior to study drug administration and no additional radiotherapy for the same lesion is planned) Patients must be weeks beyond previous treatment of any chemotherapy or radiotherapy, and must have recovered to =< grade or previous baseline for each toxicity. Exception: Patients may have received palliative low dose radiotherapy to the limbs - weeks before this therapy provided pelvis, sternum, scapulae, vertebrae, or skull were not included in the radiotherapy field. Patients who have received non-chemotherapeutic biological agents will need to wait at least half-lives or weeks, whichever is shorter, from the last day of treatment of non-chemotherapeutic biological agents. COHORT : ENDOMETRIAL CANCER: Patients who have undergone radiotherapy within weeks of first dose of study treatment Treatment with radiotherapy/radiopharmaceuticals within weeks before randomization. Radiotherapy within weeks of first dose of study medications Patients may have received prior radiation therapy in either the metastatic or early-stage setting; radiation therapy must be completed per the following timelines:\r\n* Radiotherapy to the thoracic cavity or abdomen within weeks prior to registration\r\n* Radiotherapy to bone lesions within weeks prior to registration\r\n* Radiotherapy to any other site within weeks prior to registration\r\n* NOTE: In all cases, there must be complete recovery and no ongoing complications from prior radiotherapy Patients who have had radiotherapy within < weeks are ineligible Patients who have had radiotherapy within the last weeks before the first OBP- administration. Patients who have had chemotherapy or radiotherapy within weeks of first dose of zydelig No radiotherapy within weeks Treatment must begin at a minimum of weeks after, but no later than weeks after, the date of the completion of radiotherapy Radiotherapy for primary HPVOC within weeks, or radiotherapy for any other reason within weeks prior to the first dose of vaccine Washout of weeks in case of prior chemotherapy, weeks if treatment included nitrosoureas; weeks for definitive radiotherapy, and weeks for palliative radiotherapy; months from high-dose chemotherapy and stem cell rescue; weeks from major surgery. Participants must have recovered from the acute toxic effects of all prior anticancer therapy before enrollment into the study. Any radiotherapy within weeks of registration Radiotherapy less than weeks before the first dose of study treatment or have not recovered from acute toxic effects from radiotherapy. Patients must be >= weeks beyond treatment of any chemotherapy, other investigational therapy, hormonal, biological, targeted agents or radiotherapy, and must have recovered to =< grade toxicity or previous baseline for each toxicity; exception: patients may have received palliative low dose radiotherapy to the limbs - weeks before this therapy provided pelvis, sternum, scapulae, vertebrae, or skull were not included in the radiotherapy field Patients must have completed any radiotherapy four weeks prior to study entry, - weeks for local palliative radiotherapy (XRT) (small port) The patient must have undergone prior external beam radiotherapy to a dose of - Gy to the brain stem; at least weeks but no more than weeks must have elapsed from the completion of radiotherapy Radiotherapy within the weeks prior to initiation of treatment Radiotherapy within weeks of the first dose of study drug, with the exception of palliative radiotherapy to a limited field, such as for the treatment of bone pain or a focally painful tumor mass At least weeks since the last systemic therapy or radiotherapy regimen prior to enrolment Prior radiotherapy: therapeutic radiotherapy within weeks, or palliative radiotherapy (to non-CNS disease) within week Prior radiotherapy is allowed, provided at least weeks have elapsed from completion of radiotherapy to initiation of protocol treatment Major surgery or radiotherapy within weeks of the first dose of study treatment. Patients who received prior radiotherapy to ? % of bone marrow are not eligible, irrespective of when it was received. weeks from radiotherapy Concurrent radiotherapy or radiotherapy within weeks prior to randomization or previous radiotherapy at the indicator sites (the sites that are to be followed for determination of a response) Has received radiotherapy within the days prior to first dose or within weeks for patients with glioblastoma, with the exception of palliative radiotherapy to focal lesions for pain or other symptom control. Radiotherapy or prior systemic chemotherapy within weeks Prior radiotherapy (RT) to current field of CNS disease ? weeks Radiotherapy within weeks of protocol therapy Patients who have had systemic therapy or radiotherapy within weeks prior to the first dose of study therapy Patients may have had prior radiotherapy for metastatic disease as long as it was > weeks prior to registration and the patient has recovered from adverse events associated with the radiotherapy PHASE II: Patients may have had prior radiotherapy for metastatic disease as long as it was > weeks prior to randomization and the patient has recovered from adverse events associated with the radiotherapy At least weeks after surgery or radiotherapy Radiotherapy within weeks prior to study day . Radiotherapy within weeks prior to the first dose of lenvatinib. Concurrent radiotherapy to any site or radiotherapy within weeks prior to enrollment or previous radiotherapy to the target lesion sites (the sites that are to be followed for determination of a response) Have undergone systemic radiotherapy within weeks prior to study entry, or focal radiotherapy within weeks prior to study entry. Radiotherapy to ? % of the bone marrow within weeks prior to randomization Radiotherapy within weeks of the first dose of study drug Radiotherapy within weeks of the first dose of study drug, with the exception of palliative radiotherapy to a limited field, such as for the treatment of bone pain or a focally painful tumor mass Treatment with radiotherapy within weeks prior to the first BTCTA (Mosunetuzumab) administration Prior radiotherapy within weeks of study treatment Concurrent radiotherapy to any site or radiotherapy within weeks prior to enrollment Concurrent radiotherapy to any site or radiotherapy within weeks prior to enrollment or previous radiotherapy to the target lesion sites (the sites that are to be followed for determination of a response) Radiotherapy < weeks prior to the first planned dose of study treatment Participants who have had radiotherapy within weeks prior to study entry at least weeks without tumor progression after any whole brain radiotherapy PART B: Prior radiotherapy to proposed target lesions is not permitted unless completed more than weeks prior to treatment within the study and that there has been documented progression at these sites; radiotherapy to non-target lesions is permitted within weeks of study entry provided all acute effects of the radiotherapy have resolved to =< grade Prior full field radiotherapy =< weeks or limited field radiotherapy =< weeks prior to enrollment; patients must have recovered from all therapy-related toxicities; the site of previous radiotherapy should have evidence of progressive disease if this is the only site of disease Radiotherapy within weeks prior to first dose of FOLFIRI Radiotherapy within weeks Subjects who have received systemic antitumor therapy within weeks or radiotherapy to target lesions within weeks before the first dose of study drug, which is longer Radiotherapy within weeks before enrollment. Radiotherapy within weeks before enrollment. Any major surgery, radiotherapy or immunotherapy within the weeks prior to first dose of study drug, or palliative radiotherapy to a single symptomatic lesion within the weeks prior to first dose of study drugs. Patients who received radiotherapy within weeks of entry Prior radiotherapy within weeks prior to first dose of study drug Less than three weeks since the last radiotherapy dose Participants who have received radiotherapy less than weeks prior to first dose of study medication Discontinuation of all other therapies (including other investigational drugs, radiotherapy, or chemotherapy) for the treatment of cancer ? weeks (? weeks if nitrosoureas, ? weeks if radiotherapy) before initiation of study treatment Subject has had radiotherapy or surgery within the weeks prior to treatment with ASP. At least three weeks since the last prior therapy, at least four weeks since completion of any prior radiotherapy An interval of at least weeks between prior surgical resection, weeks from the end of prior radiotherapy Radiotherapy or systemic therapy within weeks of baseline Patients who have received radiotherapy within =< weeks prior to registration Any major surgery, radiotherapy, or immunotherapy within the last weeks. Limited radiotherapy within the last weeks. Prior radiotherapy is allowed, provided at least weeks have elapsed from completion of radiotherapy to initiation of protocol treatment Radiotherapy less than weeks before the first dose of study treatment. If prior radiotherapy occurred < to weeks before study start, as radiated lesions cannot be reliably assessed by fluorodeoxyglucose-positron emission tomography (FDG-PET), nonradiated target lesions are required for eligibility, and prior radiotherapy information must be submitted to the IRC. Radiotherapy within weeks or less prior to starting first veledimex dose Subjects may not have received prior radiotherapy to the index lesion within weeks Participants who have had chemotherapy or radiotherapy within weeks ( weeks for bevacizumab) of liver resection Radiotherapy less than weeks before the first dose of study treatment. Radiotherapy to the bone marrow within weeks prior to enrollment OR within months prior to enrollment if prior radiotherapy to the craniospinal axis or to at least % of the pelvis was received; within weeks prior to enrollment if local palliative radiotherapy was received.